MK-677 (Ibutamoren mesylate)
ibutamoren · MK-0677 · nutrobal · C27H36N4O5S · CH4O3S · monoisotopic 624.2181 Da. The index holds 152 assay reports on this compound across 29 batches from 16 suppliers.
Analytical fingerprint
Hand-authored chemistry. These properties describe the substance and do not change when a record is added.
MK-677 is a small molecule, not a peptide, and the index includes it because it is submitted constantly alongside peptides and because it is analytically instructive: peptide content, counter-ion by ion chromatography and Karl Fischer water are all replaced by assay-by-HPLC against a reference standard, residual solvents by GC headspace to ICH Q3C(R8), and sulfated ash. Roughly one in six MK-677 submissions reports a purity figure with no reference standard named, and the index records those as area-percent only, which for a small molecule with unknown relative response factors is a much weaker statement than it looks.
- Compound class
- Non-peptide adjuncts
- Molecular formula
- C27H36N4O5S · CH4O3S
- Monoisotopic mass
- 624.2181Da
- Average mass
- 624.77Da
- Residues
- —
- Nominal retention (RG-2, 30 min)
- 13.86min
- Retention window
- 0.30min
- Counter-ion as usually shipped
- mesylate
- Typical label claims
- 250 mg · 500 mg · 1000 mg
- Analytical difficulty (index scale)
- 0.80 — straightforward
- Purity is a defined quantity
- YES
Representative chromatogram
Drawn from this page's own medians. Not a scan, not an illustration, and not any single report.
What the index has observed
Arithmetic over the 152 records the index holds. Aggregates on this page are computed over the records the index holds, which are not a random sample of the material on the market. Lots that get tested are lots someone chose to test. Read every figure here as a description of this dataset rather than as an estimate of a population.
By supplier
Suppliers with fewer than two purity records on this compound are omitted from the figure rather than drawn as a line. The full table, including the thin cells, is on the by-supplier page.
Characteristic impurities and degradants
The left three columns are authored chemistry — what this molecule characteristically carries and where it elutes. The right three are what the index has actually reported.
| Named species | ΔRT (min, RG-2) | Δ mass (Da) | Seen in | Median % area | Max % area |
|---|---|---|---|---|---|
| free base (des-mesylate, −96 Da) | +0.04 | -96.011 | 88% | 0.10 | 1.26 |
| sulfonamide hydrolysis product (+18 Da) | -0.86 | +18.011 | 83% | 0.17 | 1.30 |
| spiroindane regioisomer | +0.44 | mass-identical | 82% | 0.10 | 1.28 |
| residual DMF (process solvent) | -8.20 | -551.000 | 79% | 0.08 | 0.44 |
| O-desmethyl metabolite analogue (−14 Da) | -0.52 | -14.016 | 78% | 0.07 | 1.30 |
Degradation pathways
- sulfonamide hydrolysis under strongly basic conditions
- no oxidative or proteolytic liability
Full impurity profile, with what each named species implies about the synthesis →
Quarterly coverage
Most recent records
| Report | Supplier | Lot | Lab | Quarter | Purity % | Water % | Recovery % | Provenance | Flags | Result |
|---|---|---|---|---|---|---|---|---|---|---|
| AX-2026-043524 | BCH | BCH-2511-G7276 | Janoshik | 2026-Q2 | 98.36 | 4.68 | — | Supplier-supplied | 1 | FAIL |
| AX-2026-041764 | FGP | FGP-2604-K1470 | Janoshik | 2026-Q2 | 99.93 | 5.34 | — | Supplier-supplied | 1 | FAIL |
| AX-2026-043527 | BCH | BCH-2511-G7276 | Janoshik | 2026-Q2 | 98.35 | 4.36 | 95.5 | Supplier-supplied | 1 | FAIL |
| AX-2026-042409 | SWB | SWB-2605-B4738 | Medutest | 2026-Q2 | 99.32 | 2.99 | 94.9 | Laboratory-retained | 1 | FAIL |
| AX-2026-043526 | BCH | BCH-2511-G7276 | Medutest | 2026-Q2 | 97.60 | 4.50 | — | Buyer-sourced | 1 | FAIL |
| AX-2026-042410 | SWB | SWB-2605-B4738 | Janoshik | 2026-Q2 | 99.61 | 2.81 | — | Supplier-supplied | 1 | FAIL |
| AX-2026-041765 | FGP | FGP-2604-K1470 | Janoshik | 2026-Q2 | 99.93 | 5.08 | — | Supplier-supplied | 0 | FAIL |
| AX-2026-043525 | BCH | BCH-2511-G7276 | Medutest | 2026-Q2 | 98.37 | 4.32 | — | Buyer-sourced | 1 | FAIL |
| AX-2026-043530 | BCH | BCH-2511-G7276 | PeptideMeter | 2026-Q2 | 98.55 | 4.28 | 88.8 | Supplier-supplied | 2 | FAIL |
| AX-2026-043531 | BCH | BCH-2511-G7276 | Janoshik | 2026-Q2 | 98.59 | 4.34 | — | Supplier-supplied | 1 | FAIL |
| AX-2026-043529 | BCH | BCH-2511-G7276 | Janoshik | 2026-Q2 | 98.35 | 4.48 | 101.5 | Supplier-supplied | 1 | FAIL |
| AX-2026-043528 | BCH | BCH-2511-G7276 | Janoshik | 2026-Q2 | 98.35 | 4.90 | — | Supplier-supplied | 1 | FAIL |
| AX-2026-043522 | BCH | BCH-2511-G7276 | Janoshik | 2026-Q2 | 98.13 | 4.21 | 96.8 | Supplier-supplied | 1 | FAIL |
| AX-2026-043521 | BCH | BCH-2511-G7276 | Medutest | 2026-Q2 | 98.43 | 4.78 | — | Supplier-supplied | 2 | FAIL |
| AX-2026-043532 | BCH | BCH-2511-G7276 | Janoshik | 2026-Q2 | 98.18 | 4.32 | — | Laboratory-retained | 1 | FAIL |
| AX-2026-043523 | BCH | BCH-2511-G7276 | Janoshik | 2026-Q2 | 98.21 | 4.31 | — | Supplier-supplied | 1 | FAIL |
| AX-2026-043533 | BCH | BCH-2511-G7276 | VendorInvestigate | 2026-Q2 | 97.96 | 5.07 | — | Buyer-sourced | 1 | FAIL |
| AX-2026-042879 | GGPeps | GGPE-2509-T2530 | Nordanalyt | 2026-Q1 | 99.61 | 4.26 | — | Supplier-supplied | 1 | FAIL |
| AX-2026-042875 | GGPeps | GGPE-2509-T2530 | PeptideMeter | 2026-Q1 | 99.81 | 4.37 | 93.3 | Supplier-supplied | 0 | FAIL |
| AX-2026-043554 | BCH | BCH-2601-G7069 | Kestrel | 2026-Q1 | 98.39 | 4.06 | 90.4 | Supplier-supplied | 2 | FAIL |
| AX-2026-043553 | BCH | BCH-2601-G7069 | Nordanalyt | 2026-Q1 | 98.01 | 3.91 | — | Supplier-supplied | 1 | FAIL |
| AX-2026-043552 | BCH | BCH-2601-G7069 | VendorInvestigate | 2026-Q1 | 97.39 | 4.34 | 96.1 | Buyer-sourced | 1 | FAIL |
| AX-2026-043555 | BCH | BCH-2601-G7069 | Janoshik | 2026-Q1 | 97.36 | 3.41 | 104.8 | Supplier-supplied | 1 | FAIL |
| AX-2026-043551 | BCH | BCH-2601-G7069 | Janoshik | 2026-Q1 | 98.19 | 3.36 | 106.5 | Supplier-supplied | 1 | FAIL |
| AX-2026-043549 | BCH | BCH-2601-G7069 | Janoshik | 2026-Q1 | 97.89 | 4.72 | — | Supplier-supplied | 1 | FAIL |